Improving Outcome in Schizophrenia Through Identification of Genetic Risk Factors
- Conditions
- SchizophreniaSchizoaffective DisorderBipolar DisorderMajor Depression
- Interventions
- Procedure: genetic analysisProcedure: genetic assay
- Registration Number
- NCT00178932
- Lead Sponsor
- Northwestern University
- Brief Summary
The goals of this study are to replicate previous findings of genetic predictors of response to clozapine and other antipsychotic drugs.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 37
Patients with the diagnoses of schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features, or volunteers with no history of a psychotic disorder.
Patients with DSM-IV diagnoses other than schizophrenia or schizoaffective disorder, and bipolar disorder or major depression with psychotic features.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 2 Outcome in schizophrenia with other Antipsychotics genetic analysis Other Antipsychotics 1 Outcome in schizophrenia with certain antipsychotic genetic assay clozapine 1 Outcome in schizophrenia with certain antipsychotic genetic analysis clozapine 2 Outcome in schizophrenia with other Antipsychotics genetic assay Other Antipsychotics
- Primary Outcome Measures
Name Time Method We plan to compare the polymorphisms across schizophrenic patients and adults who do not have a diagnosed major mental illness. . single visit
- Secondary Outcome Measures
Name Time Method We will also evaluate relationships between the polymorphism and past and current mental health among the non-diagnosed sample single visit
Trial Locations
- Locations (1)
Psychiatric Hospital at Vanderbilt
🇺🇸Nashville, Tennessee, United States